Eib Loan Agreement

LeszlĂ© Baranyay, Vice-President of the Bei, said: “Supporting the financing of projects carried out by SMEs and ETIs is the EIB`s central objective in Slovenia, as the SME and ETI sector is the engine of growth and innovation. As part of its collaboration with SID banka, the EIB`s main partner and a major player in the Slovenian economy, the EIB ensures that the benefits of lending reach eligible promoters. Loans can be guaranteed or unsecured and offer different levels of subordination. Depending on the project, loans may even depend on the growth of the business. Sibil Svilan, President and CEO of SID banka: “Most of the SME loan will be used to finance the special SID Banka programme – a EUR 500 million programme for Slovenian SMEs, which serves as a financial instrument by combining public and private funds to provide financing favourable to the Slovenian economy. And with the energy efficiency and renewable energy loan, we will complement and enhance existing measures to stimulate investment in this area. Hedging risks related to large and small projects and loan portfolios We generally cover up to 50% of the total cost of a project with loans starting at 25 million euros and sometimes even lower amounts. Intermediate loans signed today will be renewed as part of the IIF`s Joint Action Plan for Growth in Central and South-Eastern Europe, which aims to improve access to long-term financing for European SMEs in order to mitigate the effects of the financial crisis. These funds will promote growth by improving long-term competitiveness by increasing the availability of long-term credit. STOCKHOLM, 14 October 2020 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that it has entered into a loan agreement with the European Investment Bank (EIB) that gives it access to an unsecured loan of up to 40 million euros. The loan can be used to continue to support the clinical development of melfluf and the transition from a research and development company to a fully integrated global biopharmaceutical company. Flexible loans to finance an investment program consisting of smaller projects.